International law firm Trowers & Hamlins has advised Inflexion and Rosemont Pharmaceuticals in connection with Rosemont's transfer to Inflexion's £2.3 billion continuation fund, the largest multi-asset continuation fund raised in Europe to date.
Rosemont Pharmaceuticals, a leading liquid medicines business, is one of four Inflexion portfolio companies to participate in Europe's largest multi-asset continuation fund – turbocharging the company's growth and international expansion.
Inflexion, a leading mid-market private equity house, invested in Rosemont Pharmaceuticals in 2020 and has been committed to supporting the company's growth both organically and through acquisitions.
Tim Nye, Head of the Corporate team at Trowers & Hamlins, commented:
"We acted for Inflexion on the acquisition of Rosemont in 2020 and have been working closely with the company since then as it has developed and expanded its geographical footprint. This represents a unique opportunity for Rosemont to continue its partnership with Inflexion as it looks to drive future growth. We are extremely excited for the business and look forward to working alongside it to further enhance its market leading offering."
The Trowers team was led by Private Equity Partners Tim Nye and Alison Chivers, with Claire Scanlon (Senior Associate), Rose Wakefield and Sijal Dudin (Associates) supporting from the Corporate team.
